Advertisement

American Journal of Pharmacogenomics

, Volume 3, Issue 4, pp 245–260 | Cite as

DNA Methylation Patterns in Cancer

Novel Prognostic Indicators?
  • Michael C. FrühwaldEmail author
Molecular Diagnostics

Abstract

DNA methylation is an epigenetic phenomenon influencing the normal function of DNA and its scaffolding proteins. Especially in cancer, aberrant methylation patterns may contribute to the disease process by the induction of point mutations, activation of inactive genes through hypomethylation of promoters, and transcriptional inactivation through a complex interplay with histone acetylation and other inhibitory mechanisms. Aberrant methylation patterns have been evaluated as tools in the management of patients with cancer. The predictive value, the therapeutic manipulation and the prognostic significance of aberrantly methylated gene loci have been tested in hematological as well as in solid neoplasias in adults and children. A seemingly insurmountable wealth of data has been generated, however, data on clinical associations are sometimes presented in an almost incautious fashion. Nevertheless, some genes like p15 INK4B in myelodysplastic syndrome (MDS) and p16 INK4A in some lung cancer subtypes have been shown to confer a certain prognosis. In selected cases the data have been confirmed by independent studies.

Assays have been developed that can be used by almost any clinical laboratory (e.g. methylation-specifc PCR) for the rapid and affordable screening of tumors for aberrant methylation. The study of aberrant methylation patterns has successfully entered the arena of relevant clinical applications. Importantly, methylation does not only hold the potential for being ‘just another’ biomarker, but also, as it can be reverted chemically, it is a phenomenon that holds great promise for therapeutic exploitation.

Keywords

Methylation Pattern Decitabine Aberrant Methylation Methylation Sensitive Restriction Enzyme Restriction Landmark Genomic Scanning 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgements

We thank D.J. Smiraglia, C. Plass, and J. Boos, for their helpful comments and honest criticism. We apologize to all authors in the field whose work could not be cited due to space limitations.

The author is supported by the Deutsche Krebshilfe (10-1699-Fr 1), the Deutsche Forschungsgemeinschaft (FR1516/1-1), the IZKF/Munster (Projekt G3), and the Karl Brocker Stiftung.

References

  1. 1.
    Santini V, Kantarjian HM, Issa JP. Changes in DNA methylation in neoplasia: pathophysiology and therapeutic implications. Ann Intern Med 2001; 134: 573–86PubMedGoogle Scholar
  2. 2.
    Lübbert M. DNA methylation inhibitors in the treatment of leukemias, myelodysplastic syndromes and hemoglobinopathies: clinical results and possible mechanisms of action. Curr Top Microbiol Immunol 2000; 249: 135–64PubMedCrossRefGoogle Scholar
  3. 3.
    Frühwald MC, Plass C. Global and gene-specific methylation patterns in cancer: aspects of tumor biology and clinical potential. Mol Genet Metab 2002; 75: 1–16PubMedCrossRefGoogle Scholar
  4. 4.
    Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3: 415–28PubMedCrossRefGoogle Scholar
  5. 5.
    Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002; 3: 755–63PubMedCrossRefGoogle Scholar
  6. 6.
    Sidransky D. Emerging molecular markers of cancer. Nat Rev Cancer 2002; 2: 210–9PubMedCrossRefGoogle Scholar
  7. 7.
    Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57–70PubMedCrossRefGoogle Scholar
  8. 8.
    Li E. Chromatin modification and epigenetic reprogramming in mammalian development. Nat Rev Genet 2002; 3: 662–73PubMedCrossRefGoogle Scholar
  9. 9.
    Kinzler K, Vogelstein B. Landscaping the cancer terrain. Science 1998; 280: 1036–7PubMedCrossRefGoogle Scholar
  10. 10.
    Gardiner-Garden M, Frommer M. CpG islands in vertebrate genomes. J Mol Biol 1987; 196: 261–82PubMedCrossRefGoogle Scholar
  11. 11.
    Costello JF, Frühwald MC, Smiraglia DJ, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24: 132–8PubMedCrossRefGoogle Scholar
  12. 12.
    Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860–921PubMedCrossRefGoogle Scholar
  13. 13.
    Bester TH. The DNA methyltransferases of mammals. Hum Mol Genet 2000; 9: 2395–402CrossRefGoogle Scholar
  14. 14.
    Chedin F, Lieber MR, Hsieh CL. The DNA methyltransferase-like protein DNMT3L stimulates de novo methylation by Dnmt3a. Proc Natl Acad Sci U S A 2002; 99: 16916–21PubMedCrossRefGoogle Scholar
  15. 15.
    Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res 1999; 27: 2291–8PubMedCrossRefGoogle Scholar
  16. 16.
    Plass C, Soloway PD. DNA methylation, imprinting and cancer. Eur J Hum Genet 2002; 10: 6–16PubMedCrossRefGoogle Scholar
  17. 17.
    Avner P, Heard E. X-chromosome inactivation: counting, choice and initiation. Nat Rev Genet 2001; 2: 59–67PubMedCrossRefGoogle Scholar
  18. 18.
    Comb M, Goodman HM. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 1990; 18: 3975–82PubMedCrossRefGoogle Scholar
  19. 19.
    Irvine RA, Lin IG, Hsieh CL. DNA methylation has a local effect on transcription and histone acetylation. Mol Cell Biol 2002; 22: 6689–96PubMedCrossRefGoogle Scholar
  20. 20.
    Robertson KD, Ait-Si-Ali S, Yokochi T, et al. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 2000; 25: 338–42PubMedCrossRefGoogle Scholar
  21. 21.
    Robert MF, Morin S, Beaulieu N, et al. DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 2003; 33: 61–5PubMedCrossRefGoogle Scholar
  22. 22.
    Jenuwein T, Allis CD. Translating the histone code. Science 2001; 293: 1074–80PubMedCrossRefGoogle Scholar
  23. 23.
    Fahrner JA, Eguchi S, Herman JG, et al. Dependence of histone modifications and gene expression on DNA hypermethylation in cancer. Cancer Res 2002; 62: 7213–8PubMedGoogle Scholar
  24. 24.
    Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002; 16: 6–21PubMedCrossRefGoogle Scholar
  25. 25.
    Baylin SB, Esteller M, Rountree MR, et al. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10: 687–92PubMedCrossRefGoogle Scholar
  26. 26.
    Feinberg AP, Gehrke CW, Kuo KC, et al. Reduced genomic 5-methylcytosine content in human colonic neoplasia. Cancer Res 1988; 48: 1159–61PubMedGoogle Scholar
  27. 27.
    Ehrlich M. DNA hypomethylation and cancer. In: Ehrlich M, editor. DNA alterations in cancer: genetic and epigenetic changes. Natick (MA): Eaton, 2000: 273–91Google Scholar
  28. 28.
    Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature 1983; 301: 89–92PubMedCrossRefGoogle Scholar
  29. 29.
    Qu G, Dubeau L, Narayan A, et al. Satellite DNA hypomethylation vs. overall genomic hypomethylation in ovarian epithelial tumors of different malignant potential. Mutat Res 1999; 423: 91–101PubMedCrossRefGoogle Scholar
  30. 30.
    Kondo T, Bobek MP, Kuick R, et al. Whole-genome methylation scan in ICF syndrome: hypomethylation of non-satellite DNA repeats D4Z4 and NBL2. Hum Mol Genet 2000; 9: 597–604PubMedCrossRefGoogle Scholar
  31. 31.
    Huff V. Wilms tumor genetics. Am J Med Genet 1998; 79: 260–7PubMedCrossRefGoogle Scholar
  32. 32.
    Nakagawa H, Chadwick RB, Peltomaki P, et al. From the cover: loss of imprinting of the insulin-like growth factor II gene occurs by biallelic methylation in a core region of H19-associated CTCF-binding sites in colorectal cancer. Proc Natl Acad Sci U S A 2001; 98: 591–6PubMedCrossRefGoogle Scholar
  33. 33.
    Feinberg AP, Cui H, Ohlsson R. DNA methylation and genomic imprinting: insights from cancer into epigenetic mechanisms. Semin Cancer Biol 2002; 12: 389–98PubMedCrossRefGoogle Scholar
  34. 34.
    Denissenko MF, Chen JX, Tang MS, et al. Cytosine methylation determines hot spots of DNA damage in the human P53 gene. Proc Natl Acad Sci U S A 1997; 94: 3893–8PubMedCrossRefGoogle Scholar
  35. 35.
    Denissenko MF, Pao A, Pfeifer GP, et al. Slow repair of bulky DNA adducts along the nontranscribed strand of the human p53 gene may explain the strand bias of transversion mutations in cancers. Oncogene 1998; 16: 1241–7PubMedCrossRefGoogle Scholar
  36. 36.
    Tommasi S, Denissenko MF, Pfeifer GP. Sunlight induces pyrimidine dimers preferentially at 5-methylcytosine bases. Cancer Res 1997; 57: 4727–30PubMedGoogle Scholar
  37. 37.
    Graff JR, Herman JG, Myohanen S, et al. Mapping patterns of CpG island methylation in normal and neoplastic cells implicates both upstream and downstream regions in de novo methylation. J Biol Chem 1997; 272: 22322–9PubMedCrossRefGoogle Scholar
  38. 38.
    Baylin S, Bester TH. Altered methylation patterns in cancer cell genomes: cause or consequence? Cancer Cell 2002; 1: 299–305PubMedCrossRefGoogle Scholar
  39. 39.
    Knudson Jr AG, Hethcote HW, Brown BW. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc Natl Acad Sci U S A 1975; 72: 5116–20PubMedCrossRefGoogle Scholar
  40. 40.
    Jeddeloh JA, Stokes TL, Richards EJ. Maintenance of genomic methylation requires a SWI2/SNF2-like protein. Nat Genet 1999; 22: 94–7PubMedCrossRefGoogle Scholar
  41. 41.
    Oakeley EJ. DNA methylation analysis: a review of current methodologies. Pharmacol Ther 1999; 84: 389–400PubMedCrossRefGoogle Scholar
  42. 42.
    Fraga MF, Esteller M. DNA methylation: a profile of methods and applications. Biotechniques 2002; 33: 63236–636, 649Google Scholar
  43. 43.
    Lindsay S, Bird AP. Use of restriction enzymes to detect potential gene sequences in mammalian DNA. Nature 1987; 327: 336–8PubMedCrossRefGoogle Scholar
  44. 44.
    Mateos MV, Garcia-Sanz R, Lopez-Perez R, et al. Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 2002; 118: 1034–40PubMedCrossRefGoogle Scholar
  45. 45.
    Clark SJ, Harrison J, Paul CL, et al. High sensitivity mapping of methylated cytosines. Nucleic Acids Res 1994; 22: 2990–7PubMedCrossRefGoogle Scholar
  46. 46.
    Herman JG, Graff JR, Myohanen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996; 93: 9821–6PubMedCrossRefGoogle Scholar
  47. 47.
    Anker P, Mulcahy H, Stroun M. Circulating nucleic acids in plasma and serum as a noninvasive investigation for cancer: time for large-scale clinical studies? Int J Cancer 2003; 103: 149–52PubMedCrossRefGoogle Scholar
  48. 48.
    Ziegler A, Zangemeister-Wittke U, Stahel RA. Circulating DNA: a new diagnostic gold mine? Cancer Treat Rev 2002; 28: 255–71PubMedCrossRefGoogle Scholar
  49. 49.
    Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002; 18: 1427–31PubMedCrossRefGoogle Scholar
  50. 50.
    Eads CA, Danenberg KD, Kawakami K, et al. MethyLight: a high-throughput assay to measure DNA methylation. Nucleic Acids Res 2000; 28: E32PubMedCrossRefGoogle Scholar
  51. 51.
    Wei SH, Chen CM, Strathdee G, et al. Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res 2002; 8: 2246–52PubMedGoogle Scholar
  52. 52.
    Frühwald MC, O’Dorisio MS, Dai Z, et al. Aberrant promoter methylation of previously unidentified target genes is a common abnormality in medulloblastomas: implications for tumor biology and potential clinical utility. Oncogene 2001; 20: 5033–42PubMedCrossRefGoogle Scholar
  53. 53.
    Tan EM, Schur PH, Carr RI, et al. Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest 1966; 45: 1732–40PubMedCrossRefGoogle Scholar
  54. 54.
    Usadel H, Brabender J, Danenberg KD, et al. Quantitative adenomatous polyposis coli promoter methylation analysis in tumor tissue, serum, and plasma DNA of patients with lung cancer. Cancer Res 2002; 62: 371–5PubMedGoogle Scholar
  55. 55.
    Maloney KW, McGavran L, Odom LF, et al. Acquisition of p16(INK4A) and p15(INK4B) gene abnormalities between initial diagnosis and relapse in children with acute lymphoblastic leukemia. Blood 1999; 93: 2380–5PubMedGoogle Scholar
  56. 56.
    Palmisano WA, Divine KK, Saccomanno G, et al. Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 2000; 60: 5954–8PubMedGoogle Scholar
  57. 57.
    Evron E, Dooley WC, Umbricht CB, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001; 357: 1335–6PubMedCrossRefGoogle Scholar
  58. 58.
    Goessl C, Krause H, Muller M, et al. Fluorescent methylation-specific polymerase chain reaction for DNA-based detection of prostate cancer in bodily fluids. Cancer Res 2000; 60: 5941–5PubMedGoogle Scholar
  59. 59.
    Levine MN, Browman GP, Gent M, et al. When is a prognostic factor useful: a guide for the perplexed. J Clin Oncol 1991; 9: 348–56PubMedGoogle Scholar
  60. 60.
    Lardot C, Steward W, Van Glabbeke M, et al. Scientific review of EORTC trials: the functioning of the New Treatment Committee and Protocol Review Committee. Eur J Cancer 2002; 38Suppl. 4: S24–30PubMedCrossRefGoogle Scholar
  61. 61.
    Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531–7PubMedCrossRefGoogle Scholar
  62. 62.
    Quesnel B, Guillerm G, Vereecque R, et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998; 91: 2985–90PubMedGoogle Scholar
  63. 63.
    Tien HF, Tang JH, Tsay W, et al. Methylation of the p15(INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 2001; 112: 148–54PubMedCrossRefGoogle Scholar
  64. 64.
    Roman-Gomez J, Castillejo JA, Jimenez A, et al. 5′ CpG island hypermethylation is associated with transcriptional silencing of the p21(CIP1/WAF1/SDI1) gene and confers poor prognosis in acute lymphoblastic leukemia. Blood 2002; 99: 2291–6PubMedCrossRefGoogle Scholar
  65. 65.
    Roman J, Castillejo JA, Jimenez A, et al. Hypermethylation of the calcitonin gene in acute lymphoblastic leukaemia is associated with unfavourable clinical outcome. Br J Haematol 2001; 113: 329–38PubMedCrossRefGoogle Scholar
  66. 66.
    Hoshino K, Asou N, Okubo T, et al. The absence of the p15INK4B gene alterations in adult patients with precursor B-cell acute lymphoblastic leukaemia is a favourable prognostic factor. Br J Haematol 2002; 117: 531–40PubMedCrossRefGoogle Scholar
  67. 67.
    Garcia-Manero G, Jeha S, Daniel J, et al. Aberrant DNA methylation in pediatric patients with acute lymphocytic leukemia. Cancer 2003; 97: 695–702PubMedCrossRefGoogle Scholar
  68. 68.
    Chim CS, Liang R, Tam CY, et al. Methylation of p15 and p16 genes in acute promyelocytic leukemia: potential diagnostic and prognostic significance. J Clin Oncol 2001; 19: 2033–40PubMedGoogle Scholar
  69. 69.
    Issa JP, Kantarjian H, Mohan A, et al. Methylation of the ABL1 promoter in chronic myelogenous leukemia: lack of prognostic significance. Blood 1999; 93: 2075–80PubMedGoogle Scholar
  70. 70.
    Asimakopoulos FA, Shteper PJ, Krichevsky S, et al. ABL1 methylation is a distinct molecular event associated with clonal evolution of chronic myeloid leukemia. Blood 1999; 94: 2452–60PubMedGoogle Scholar
  71. 71.
    Garcia MJ, Martinez-Delgado B, Cebrian A, et al. Different incidence and pattern of p15INK4b and p16INK4a promoter region hypermethylation in Hodgkin’s and CD30-positive non-Hodgkin’s lymphomas. Am J Pathol 2002; 161: 1007–13PubMedCrossRefGoogle Scholar
  72. 72.
    Gronbaek K, de Nully Brown P, Moller MB, et al. Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin’s lymphoma. Leukemia 2000; 14: 1727–35PubMedCrossRefGoogle Scholar
  73. 73.
    Esteller M, Gaidano G, Goodman SN, et al. Hypermethylation of the DNA repair gene O(6)-methylguanine DNA methyltransferase and survival of patients with diffuse large B-cell lymphoma. J Natl Cancer Inst 2002; 94: 26–32PubMedCrossRefGoogle Scholar
  74. 74.
    Belinsky SA, Nikula KJ, Palmisano WA, et al. Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis. Proc Natl Acad Sci U S A 1998; 95: 11891–6PubMedCrossRefGoogle Scholar
  75. 75.
    Lamy A, Sesboue R, Bourguignon J, et al. Aberrant methylation of the CDKN2a/p16INK4a gene promoter region in preinvasive bronchial lesions: a prospective study in high-risk patients without invasive cancer. Int J Cancer 2002; 100: 189–93PubMedCrossRefGoogle Scholar
  76. 76.
    Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001; 61: 3419–24PubMedGoogle Scholar
  77. 77.
    Esteller M, Sanchez-Cespedes M, Rosell R, et al. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59: 67–70PubMedGoogle Scholar
  78. 78.
    Brabender J, Usadel H, Danenberg KD, et al. Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival. Oncogene 2001; 20: 3528–32PubMedCrossRefGoogle Scholar
  79. 79.
    Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691–9PubMedCrossRefGoogle Scholar
  80. 80.
    Sanchez-Cespedes M, Esteller M, Wu L, et al. Gene promoter hypermethylation in tumors and serum of head and neck cancer patients. Cancer Res 2000; 60: 892–5PubMedGoogle Scholar
  81. 81.
    Ogi K, Toyota M, Ohe-Toyota M, et al. Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clin Cancer Res 2002; 8: 3164–71PubMedGoogle Scholar
  82. 82.
    Chang HW, Chow V, Lam KY, et al. Loss of E-cadherin expression resulting from promoter hypermethylation in oral tongue carcinoma and its prognostic significance. Cancer 2002; 94: 386–92PubMedCrossRefGoogle Scholar
  83. 83.
    Kawakami K, Brabender J, Lord RV, et al. Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma. J Natl Cancer Inst 2000; 92: 1805–11PubMedCrossRefGoogle Scholar
  84. 84.
    Kang GH, Shim YH, Jung HY, et al. CpG island methylation in premalignant stages of gastric carcinoma. Cancer Res 2001; 61: 2847–51PubMedGoogle Scholar
  85. 85.
    Lee S, Kim WH, Jung HY, et al. Aberrant CpG island methylation of multiple genes in intrahepatic cholangiocarcinoma. Am J Pathol 2002; 161: 1015–22PubMedCrossRefGoogle Scholar
  86. 86.
    Wong IH, Lo YM, Zhang J, et al. Detection of aberrant p16 methylation in the plasma and serum of liver cancer patients. Cancer Res 1999; 59: 71–3PubMedGoogle Scholar
  87. 87.
    Zou HZ, Yu BM, Wang ZW, et al. Detection of aberrant p16 methylation in the serum of colorectal cancer patients. Clin Cancer Res 2002; 8: 188–91PubMedGoogle Scholar
  88. 88.
    Esteller M, Gonzalez S, Risques RA, et al. K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. J Clin Oncol 2001; 19: 299–304PubMedGoogle Scholar
  89. 89.
    Kanazawa T, Watanabe T, Kazama S, et al. Poorly differentiated adenocarcinoma and mucinous carcinoma of the colon and rectum show higher rates of loss of heterozygosity and loss of E-cadherin expression due to methylation of promoter region. Int J Cancer 2002; 102: 225–9PubMedCrossRefGoogle Scholar
  90. 90.
    Nakayama H, Hibi K, Taguchi M, et al. Molecular detection of p16 promoter methylation in the serum of colorectal cancer patients. Cancer Lett 2002; 188: 115–9PubMedCrossRefGoogle Scholar
  91. 91.
    van Rijnsoever M, Grieu F, Elsaleh H, et al. Characterisation of colorectal cancers showing hypermethylation at multiple CpG islands. Gut 2002; 51: 797–802PubMedCrossRefGoogle Scholar
  92. 92.
    Brauch H, Weirich G, Brieger J, et al. VHL alterations in human clear cell renal cell carcinoma: association with advanced tumor stage and a novel hot spot mutation. Cancer Res 2000; 60: 1942–8PubMedGoogle Scholar
  93. 93.
    Tada Y, Wada M, Taguchi K, et al. The association of death-associated protein kinase hypermethylation with early recurrence in superficial bladder cancers. Cancer Res 2002; 62: 4048–53PubMedGoogle Scholar
  94. 94.
    Tada Y, Wada M, Kuroiwa K, et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. Clin Cancer Res 2000; 6: 4618–27PubMedGoogle Scholar
  95. 95.
    Dominguez G, Carballido J, Silva J, et al. pl4ARF promoter hypermethylation in plasma DNA as an indicator of disease recurrence in bladder cancer patients. Clin Cancer Res 2002; 8: 980–5PubMedGoogle Scholar
  96. 96.
    Li LC, Chui R, Nakajima K, et al. Frequent methylation of estrogen receptor in prostate cancer: correlation with tumor progression. Cancer Res 2000; 60: 702–6PubMedGoogle Scholar
  97. 97.
    Zysman M, Saka A, Millar A, et al. Methylation of adenomatous polyposis coli in endometrial cancer occurs more frequently in tumors with microsatellite instability phenotype. Cancer Res 2002; 62: 3663–6PubMedGoogle Scholar
  98. 98.
    Virmani AK, Muller C, Rathi A, et al. Aberrant methylation during cervical carcinogenesis. Clin Cancer Res 2001; 7: 584–9PubMedGoogle Scholar
  99. 99.
    Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. V Engl J Med 2000; 343: 1350–4CrossRefGoogle Scholar
  100. 100.
    Soares J, Pinto AE, Cunha CV, et al. Global DNA hypomethylation in breast carcinoma: correlation with prognostic factors and tumor progression. Cancer 1999; 85: 112–8PubMedCrossRefGoogle Scholar
  101. 101.
    Eads CA, Lord RV, Wickramasinghe K, et al. Epigenetic patterns in the progression of esophageal adenocarcinoma. Cancer Res 2001; 61: 3410–8PubMedGoogle Scholar
  102. 102.
    Itano O, Ueda M, Kikuchi K, et al. A new predictive factor for hepatocellular carcinoma based on two-dimensional electrophoresis of genomic DNA. Oncogene 2000; 19: 1676–83PubMedCrossRefGoogle Scholar
  103. 103.
    Wijermans P, Lubbert M, Verhoef G, et al. Low-dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J Clin Oncol 2000; 18: 956–62PubMedGoogle Scholar
  104. 104.
    Goffin J, Eisenhauer E. DNA methyltransferase inhibitors-state of the art. Ann Oncol 2002; 13: 1699–716PubMedCrossRefGoogle Scholar
  105. 105.
    Slack A, Bovenzi V, Bigey P, et al. Antisense MBD2 gene therapy inhibits tumorigenesis. J Gene Med 2002; 4: 381–9PubMedCrossRefGoogle Scholar
  106. 106.
    Ramchandani S, MacLeod AR, Pinard M, et al. Inhibition of tumorigenesis by a cytosine-DNA, methyltransferase, antisense oligodeoxynucleotide. Proc Natl Acad Sci U S A 1997; 94: 684–9PubMedCrossRefGoogle Scholar
  107. 107.
    Chuang LS, Tan EH, Oh HK, et al. Selective depletion of human DNA-methyltransferase DNMT1 proteins by sulfonate-derived methylating agents. Cancer Res 2002; 62: 1592–7PubMedGoogle Scholar
  108. 108.
    Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999; 21: 103–7PubMedCrossRefGoogle Scholar
  109. 109.
    Weber BL. Cancer genomics. Cancer Cell 2002; 1: 37–47PubMedCrossRefGoogle Scholar
  110. 110.
    Shi H, Maier S, Nimmrich I, et al. Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J Cell Biochem 2003; 88: 138–43PubMedCrossRefGoogle Scholar
  111. 111.
    Stach D, Schmitz OJ, Stilgenbauer S, et al. Capillary electrophoretic analysis of genomic DNA methylation levels. Nucleic Acids Res 2003; 31: E2PubMedCrossRefGoogle Scholar
  112. 112.
    Leone G, Teofili L, Voso MT, et al. DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. Haematologica 2002; 87: 1324–41PubMedGoogle Scholar
  113. 113.
    Daskalakis M, Nguyen TT, Nguyen C, et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 2002; 100: 2957–64PubMedCrossRefGoogle Scholar
  114. 114.
    Silverman LR, Demakos EP, Peterson BL, et al. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 2002; 20: 2429–40PubMedCrossRefGoogle Scholar
  115. 115.
    Kornblith AB, Herndon II JE, Silverman LR, et al. Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 2002; 20: 2441–52PubMedCrossRefGoogle Scholar
  116. 116.
    Garcia-Manero G, Bueso-Ramos C, Daniel J, et al. DNA methylation patterns at relapse in adult acute lymphocytic leukemia. Clin Cancer Res 2002; 8: 1897–903PubMedGoogle Scholar
  117. 117.
    Garcia-Manero G, Daniel J, Smith TL, et al. DNA methylation of multiple promoter-associated CpG islands in adult acute lymphocytic leukemia. Clin Cancer Res 2002; 8: 2217–24PubMedGoogle Scholar
  118. 118.
    Zion M, Ben-Yehuda D, Avraham A, et al. Progressive de novo DNA methylation at the bcr-abl locus in the course of chronic myelogenous leukemia. Proc Natl Acad Sci U S A 1994; 91: 10722–6PubMedCrossRefGoogle Scholar
  119. 119.
    Harada K, Toyooka S, Maitra A, et al. Aberrant promoter methylation and silencing of the RASSF1A gene in pediatric tumors and cell lines. Oncogene 2002; 21: 4345–9PubMedCrossRefGoogle Scholar
  120. 120.
    Lengauer C, Kinzler KW, Vogelstein B. DNA methylation and genetic instability in colorectal cancer cells. Proc Natl Acad Sci U S A 1997; 94: 2545–50PubMedCrossRefGoogle Scholar
  121. 121.
    Issa JP, Ottaviano YL, Celano P, et al. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7: 536–40PubMedCrossRefGoogle Scholar
  122. 122.
    Issa JP, Vertino PM, Wu J, et al. Increased cytosine DNA-methyltransferase activity during colon cancer progression. J Natl Cancer Inst 1993; 85: 1235–40PubMedCrossRefGoogle Scholar
  123. 123.
    Toyota M, Ahuja N, Ohe-Toyota M, et al. CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci U S A 1999; 96: 8681–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Department of Pediatric Hematology And OncologyChildren’s Hospital MünsterMünsterGermany

Personalised recommendations